Tag - Esther Hong

Janney Montgomery Scott initiated coverage of Spero Therapeutics (NASDAQ:SPRO) with a “buy” rating and fair value estimate of $27. The stock closed at $9.98 on Sept. 6. Analyst Esther Hong writes that her initiation is...